Cited by 3,421Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsIntraperitoneal and Appendiceal Malignancies

The DOI matches its Crossref record; 303 of the 309 references it cites were found in a registry or an index.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Open access

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J.H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W.J.G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T.J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H.J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., Arnold, D.·2016·Annals of Oncology

DOI 10.1093/annonc/mdw235

Open this paper in CoChat — free account Open PDF

Abstract

Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particular, the clinical outcome for patients with metastatic CRC (mCRC) has improved greatly due not only to an increase in the number of patients being referred for and undergoing surgical resection of their localised metastatic disease but also to a more strategic approach to the delivery of systemic therapy and an expansion in the use of ablative techniques. This reflects the increase in the number of patients that are being managed within a multidisciplinary team environment and specialist cancer centres, and the emergence over the same time period not only of improved imaging techniques but also prognostic and predictive molecular markers. Treatment decisions for patients with mCRC must be evidence-based. Thus, these ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdw235

Cites

303 of 303 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova‐Foucher, E., Lortet‐Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,243
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Self-citation
Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer
Fong, Y., Fortner, J. G., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999) · Annals of Surgery · doi:10.1097/00000658-199909000-00004 · Cited by 3,722

Show all 309 references

Research works printed but not linked: 6

Stintzing, 2013, Analysis of KRAS/NRAS and BRAF mutations in FIRE-3, Eur J Cancer, 49
Venook, 2014, J Clin Oncol, 32
Collettini, 2012, Percutaneous CT-guided high-dose brachytherapy (CT-HDRBT) ablation of primary and metastatic lung tumors in nonsurgical candidates, Rofo, 184, 316
Lenz, 2014, Ann Oncol, 25
Garcia Alfonso, 2014, Ann Oncol, 25
Cascinu, 2015, Eur J Cancer, 51

Sorted by citations

Items 201–300 of 1,003

Distant Metastasis in Colorectal Cancer Patients—Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review
Filip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 86
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
Antoniotti, C., Borelli, B., Rossini, D., Pietrantonio, F., Morano, F., Salvatore, L., Lonardi, S., Marmorino, F., Tamberi, S., Corallo, S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07169-6 · Cited by 82
Self-citation
Factors Associated With Local Tumor Control and Complications After Thermal Ablation of Colorectal Cancer Liver Metastases: A 15-year Retrospective Cohort Study
Kurilova, I., Bendet, A., Petre, E. N., Boas, F. E., Kaye, E., Gönen, M., Covey, A. M., Brody, L. A., Brown, K. T., Kemeny, N. E., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.09.005 · Cited by 80
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
Aranda, E., Alfonso, P. G., Benavides, M., Ruiz, A. C. S., Guillén‐Ponce, C., Safont, M. J., Alcaide, J., Gómez, A., López‐López, R., Manzano, J. L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.024 · Cited by 80
The landscape of cancer-associated fibroblasts in colorectal cancer liver metastases
Giguelay, A., Turtoi, E., Khellaf, L., Tosato, G., Dadi, I., Chastel, T., Poul, M., Pratlong, M., Nicolescu, S., Séverac, D., et al. (2022) · Theranostics · doi:10.7150/thno.72853 · Cited by 79
ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance
Tsoumas, D., Nikou, S., Giannopoulou, E., Tsaniras, S. C., Sirinian, C., Maroulis, I. C., Taraviras, S. L., Zolota, V., Kalofonos, H. P., & Bravou, V. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20071 · Cited by 79
Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review
Kobiela, J., Spychalski, P., Marvaso, G., Ciardo, D., Dell’Acqua, V., Kraja, F., Błażyńska‐Spychalska, A., Łachiński, A. J., Surgo, A., Glynne‐Jones, R., et al. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.005 · Cited by 78
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities
Mauri, G., Gori, V., Bonazzina, E. F., Amatu, A., Tosi, F., Bencardino, K. B., Ruggieri, L., Patelli, G., Arena, S., Bardelli, A., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102112 · Cited by 80
Self-citation
Recent advances in (chemo-)radiation therapy for rectal cancer: a comprehensive review
Roeder, F., Meldolesi, E., Gerum, S., Valentini, V., & Rödel, C. M. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01695-0 · Cited by 77
Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress
Rastin, F., Javid, H., Oryani, M. A., Rezagholinejad, N., Afshari, A. R., & Karimi‐Shahri, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111055 · Cited by 86
Targeting Angiogenesis in Colorectal Carcinoma
Lopez, A., Harada, K., Vassilakopoulou, M., Shanbhag, N. D., & Ajani, J. A. (2019) · Drugs · doi:10.1007/s40265-018-1037-9 · Cited by 80
KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
Garcia-Carbonero, N., Martínez‐Useros, J., Li, W., Orta, A., Pérez, N. T. I., Caramés, C., Hernández, T., Moreno, I., Serrano, G., & García‐Foncillas, J. (2020) · Cells · doi:10.3390/cells9010219 · Cited by 81
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taïeb, J., Jung, A., Bianchi, A. S., Peeters, M., Seligmann, J. F., Zaanan, A., Burdon, P., Montagut, C. O., & Laurent‐Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 78
Self-citation
Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons
Ignatavičius, P., Oberkofler, C. E., Chapman, W. C., DeMatteo, R. P., Clary, B. M., D'Angelica, M. I., Tanabe, K. K., Hong, J. C., Aloia, T. A., Pawlik, T. M., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004331 · Cited by 76
Self-citation
Overall survival of colorectal cancer by stage at diagnosis
Joachim, C., Macni, J., Dramé, M., Pomier, A., Escarmant, P., Véronique-Baudin, J., & Vinh‐Hung, V. (2019) · Medicine · doi:10.1097/md.0000000000016941 · Cited by 75
Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta‐analysis
Narasimhan, V., Tan, S. H., Kong, J. C. H., Pham, T. D., Michael, M., Ramsay, R. G., Warrier, S. K., & Heriot, A. G. (2020) · Colorectal Disease · doi:10.1111/codi.15003 · Cited by 75
Trends, clinicopathological features, surgical treatment patterns and prognoses of early-onset versus late-onset colorectal cancer: A retrospective cohort study on 34067 patients managed from 2000 to 2021 in a Chinese tertiary center
Gao, X., Li, J., Liu, L., Zheng, N. X., Zheng, K., Mei, Z., Bai, C. G., & Zhang, W. (2022) · International Journal of Surgery · doi:10.1016/j.ijsu.2022.106780 · Cited by 75
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
Arnold, D., Prager, G. W., Quintela, A., Stein, A., Vera, S. R. M., Mounedji, N., & Taı̈eb, J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy038 · Cited by 75
Self-citation
Efficacy of bevacizumab in first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis
Baraniskin, A., Buchberger, B., Pox, C. P., Graeven, U., Holch, J. W., Schmiegel, W., & Heinemann, V. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.009 · Cited by 75
Self-citation
The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: a review of a 4-year experience at a single center
Qin, S., Liu, G., Huang, M., Huang, J. C., Luo, Y., Wen, Y., Wang, Y., & Chen, L. (2018) · International Journal of Hyperthermia · doi:10.1080/02656736.2018.1528511 · Cited by 74
How to increase the resectability of initially unresectable colorectal liver metastases: A surgical perspective
Imai, K., Adam, R. A., & Baba, H. (2019) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12276 · Cited by 74
Self-citation
Exploring the best treatment options for BRAF-mutant metastatic colon cancer
Taı̈eb, J., Lapeyre-Prost, A., Laurent‐Puig, P., & Zaanan, A. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0526-2 · Cited by 76
Self-citation
Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis
Facciorusso, A., Aziz, M. A. A. E., & Sacco, R. (2019) · Cancers · doi:10.3390/cancers12010036 · Cited by 74
Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study
Øgaard, N., Reinert, T., Henriksen, T. V., Frydendahl, A., Aagaard, E. M. N., Ørntoft, M. W., Larsen, M. Ø., Knudsen, A. R., Mortensen, F. V., & Andersen, C. L. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.026 · Cited by 72
The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer
Mauri, G., Bonazzina, E., Amatu, A., Tosi, F., Bencardino, K., Gori, V., Massihnia, D., Cipani, T., Spina, F., Ghezzi, S., et al. (2021) · Cancers · doi:10.3390/cancers13010137 · Cited by 73
Diagnostic performance of gadoxetic acid–enhanced liver MRI versus multidetector CT in the assessment of colorectal liver metastases compared to hepatic resection
Granata, V., Fusco, R., di Castelguidone, E. D. L., Avallone, A., Palaia, R., Delrio, P., Tatangelo, F., Botti, G., Grassi, R., Izzo, F., et al. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1036-7 · Cited by 73
Mucoadhesive-to-penetrating controllable peptosomes-in-microspheres co-loaded with anti-miR-31 oligonucleotide and Curcumin for targeted colorectal cancer therapy
Zhao, R., Du, S., Liu, Y., Lv, C., Song, Y., Chen, X., Zhang, B., Li, D., Gao, S., Cui, W., et al. (2020) · Theranostics · doi:10.7150/thno.40318 · Cited by 74
Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression
Silva, M. C., Fernandes, Â., Oliveira, M. J., Resende, C., Correia, A., de‐Freitas‐Junior, J. C. M., Lavelle, A., Andrade-da-Costa, J., Leander, M., Xavier‐Ferreira, H., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0264 · Cited by 84
Results and challenges of immune checkpoint inhibitors in colorectal cancer
Emambux, S., Tachon, G., Junca, A., & Tougeron, D. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1445222 · Cited by 74
Intratumor CMS heterogeneity impacts patient prognosis in localized colon cancer
Marisa, L., Blum, Y., Taieb, J., Ayadi, M., Pilati, C., Le Malicot, K., Lepage, C., Salazar, R., Aust, D., Duval, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0529 · Cited by 68
Self-citation
Comparison of the guidelines for colorectal cancer in Japan, the USA and Europe
Shinagawa, T., Tanaka, T., Nozawa, H., Emoto, S., Murono, K., Kaneko, M., Sasaki, K., Otani, K., Nishikawa, T., Hata, K., et al. (2017) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12047 · Cited by 72
Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study
Jensen, L. H., Rogatto, S. R., Lindebjerg, J., Havelund, B. M., Abildgaard, C., do Canto, L. M., Vagn-Hansen, C., Dam, C., Rafaelsen, S. R., & Hansen, T. F. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02683-4 · Cited by 74
Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial
Winther, S. B., Liposits, G. I., Skúladóttir, H., Hofsli, E., Shah, C.-H., Poulsen, L. Ø., Ryg, J., Osterlund, P. J., Berglund, Å., Qvortrup, C., et al. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30041-x · Cited by 73
Self-citation
All You Need to Know About UGT1A1 Genetic Testing for Patients Treated With Irinotecan: A Practitioner-Friendly Guide
Karas, S., & Innocenti, F. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00624 · Cited by 76
Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy
Allen, W. L., Dunne, P. D., McDade, S. S., Scanlon, E. E., Loughrey, M. B., Coleman, H. G., McCann, C. K., McLaughlin, K., Németh, Z., Syed, N., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00241 · Cited by 71
Self-citation
Colorectal cancer: Genetic alterations, novel biomarkers, current therapeutic strategies and clinical trials
Housini, M., Dariya, B., Ahmed, N., Stevens, A., Fiadjoe, H. K., Nagaraju, G. P., & Basha, R. M. (2023) · Gene · doi:10.1016/j.gene.2023.147857 · Cited by 74
ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review
Beets, G. L., Sebag‐Montefiore, D., Andritsch, E., Arnold, D., Beishon, M., Crul, M., Dekker, J. W. T., Bolton, R. C. D., Fléjou, J., Grisold, W., et al. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.12.001 · Cited by 71
Self-citation
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients
Ruzzo, A., Graziano, F., Galli, F., Galli, F., Rulli, E., Lonardi, S., Ronzoni, M., Massidda, B., Zagonel, V., Pella, N., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.289 · Cited by 71
Self-citation
Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes
Boas, F. E., Bodei, L., & Sofocleous, C. T. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.187229 · Cited by 71
Dual-energy CT in patients with colorectal cancer: Improved assessment of hypoattenuating liver metastases using noise-optimized virtual monoenergetic imaging
Lenga, L., Czwikla, R., Wichmann, J. L., Leithner, D., Albrecht, M. H., Booz, C., Arendt, C. T., Yel, İ., D’Angelo, T., Vogl, T. J., et al. (2018) · European Journal of Radiology · doi:10.1016/j.ejrad.2018.07.027 · Cited by 70
Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient’s Stratification
Ginghină, O., Hudiță, A., Zamfir, M., Spânu, A., Mardare, M., Bondoc, I., Buburuzan, L., Georgescu, S. E., Costache, M., Negrei, C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.856575 · Cited by 78
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF V600E -Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study
Stintzing, S., Heinrich, K., Tougeron, D., Modest, D. P., Schwaner, I., Eucker, J., Pihusch, R., Stauch, M. B., Kaiser, F., Kahl, C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01420 · Cited by 73
Self-citation
Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review
Skårderud, M. R., Dyhl-Polk, A., Vistisen, K. K., Larsen, F. O., & Nielsen, D. L. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.011 · Cited by 71
The role of tumor angiogenesis as a therapeutic target in colorectal cancer
Battaglin, F., Puccini, A., Intini, R., Schirripa, M., Ferro, A., Bergamo, F., Lonardi, S., Zagonel, V., Lenz, H., & Loupakis, F. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1428092 · Cited by 75
Comparative dosimetry between 99mTc-MAA SPECT/CT and 90Y PET/CT in primary and metastatic liver tumors
Jadoul, A., Bernard, C., Lovinfosse, P., Gérard, L., Lilet, H., Cornet, O., & Hustinx, R. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04465-7 · Cited by 70
Microwave ablation versus resection for colorectal cancer liver metastases – A propensity score analysis from a population-based nationwide registry
Tinguely, P., Dal, G., Bottai, M., Nilsson, H., Freedman, J., & Engstrand, J. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.12.002 · Cited by 69
The Evolving Treatment Landscape in BRAF-V600E –Mutated Metastatic Colorectal Cancer
Tabernero, J. M., Ros, J., & Élez, E. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349561 · Cited by 71
Self-citation
Impact of post-hepatectomy liver failure on morbidity and short- and long-term survival after major hepatectomy
Baumgartner, R., Gilg, S., Björnsson, B., Hasselgren, K., Ghorbani, P., Sauter, C., Stal, P. I., Sandstöm, P., Sparrelid, E., & Engstrand, J. (2022) · BJS Open · doi:10.1093/bjsopen/zrac097 · Cited by 68
Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
Sur, D. G., Havasi, A. D., Cainap, C. I., Samaşcă, G., Burz, C. C., Bălăcescu, O., Lupan, I., Deleanu, D. M., & Irimie, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010182 · Cited by 67
Tumor-Selective Immune-Active Mild Hyperthermia Associated with Chemotherapy in Colon Peritoneal Metastasis by Photoactivation of Fluorouracil–Gold Nanoparticle Complexes
Mulens‐Arias, V., Nicolás‐Boluda, A., Pinto, A., Balfourier, A., Carn, F., Silva, A., Pocard, M. D., & Gazeau, F. (2021) · ACS Nano · doi:10.1021/acsnano.0c10276 · Cited by 68
Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
Aparicio, J., Esposito, F. M., Serrano, S., Falcó, E., Escudero, P., Ruiz‐Casado, A., Manzano, H., & Montés, A. F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123889 · Cited by 71
Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
Amodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 67
Self-citation
The Epidemiology of Lung Metastases
Chen, H., Stoltzfus, K. C., Lehrer, E. J., Horn, S. R., Siva, S., Trifiletti, D. M., Meng, M.-B., Verma, V., Louie, A. V., & Zaorsky, N. G. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.723396 · Cited by 71
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest
Cremolini, C., Casagrande, M., Loupakis, F., Aprile, G., Bergamo, F., Masi, G., Roberto, R. N. D. G., Pietrantonio, F., Marmorino, F., Zucchelli, G., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.028 · Cited by 67
Self-citation
Molecular classifications of gastric cancers: Novel insights and possible future applications
Garattini, S. K., Basile, D., Cattaneo, M., Fanotto, V., Ongaro, E., Bonotto, M., Negri, F., Berenato, R., Ermacora, P., Cardellino, G. G., et al. (2017) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v9.i5.194 · Cited by 66
Colorectal Cancer: Why Does Side Matter?
Gallois, C., Pernot, S., Zaanan, A., & Taı̈eb, J. (2018) · Drugs · doi:10.1007/s40265-018-0921-7 · Cited by 68
Self-citation
Recurrence Risk after Radical Colorectal Cancer Surgery—Less Than before, But How High Is It?
Osterman, E., Hammarström, K., Imam, I., Österlund, E., Sjöblom, T., & Glimelius, B. L. G. (2020) · Cancers · doi:10.3390/cancers12113308 · Cited by 66
The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up
de Baère, T., Woodrum, D. A., Tselikas, L., Abtin, F. G., Littrup, P. J., Deschamps, F., Suh, R. D., Aoun, H. D., & Callstrom, M. R. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.021 · Cited by 65
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
Cutsem, E. V., Yoshino, T., Lenz, H., Lonardi, S., Falcone, A., Limón, M. L., Saunders, M. P., Sobrero, A. F., Park, Y. S., Ferreiro, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy241 · Cited by 65
Self-citation
BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies
van Brummelen, E. M. J., de Boer, A., Beijnen, J. H., & Schellens, J. H. M. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0031 · Cited by 64
Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review
Bolhuis, K., Kos, M., van Oijen, M. G. H., Swijnenburg, R., & Punt, C. J. A. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.037 · Cited by 66
Self-citation
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
Ros, J., Baraibar, I., Sardo, E., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Ciardiello, D., Cuadra‐Urteaga, J. L., Tabernero, J. M., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992974 · Cited by 68
Self-citation
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
Cohen, R., Cervera, P., Svrcek, M., Pellat, A., Dreyer, C., de Gramont, A., & André, T. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0453-5 · Cited by 64
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study
Yoshino, T., Portnoy, D. C., Obermannova, R. L., Bodoky, G., Prausová, J., García‐Carbonero, R., Ciuleanu, T., Alfonso, P. G., Cohn, A. L., Cutsem, E. V., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy461 · Cited by 64
Self-citation
Evolution and revolution of laparoscopic liver resection in Japan
Kaneko, H., Otsuka, Y., Kubota, Y., & Wakabayashi, G. (2017) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12000 · Cited by 63
Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer
Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C. (2022) · Cancers · doi:10.3390/cancers14194874 · Cited by 62
Oral drugs in the treatment of metastatic colorectal cancer
Alfonso, P. G., Martín, A. J. M., Morán, L. O., Alsar, J. S., Pérez-Solero, G. T., Codesido, M. B., Ferrandiz, P. A. C., & Cicala, S. G. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211009001 · Cited by 61
Targeting EGFR and RAS/RAF Signaling in the Treatment of Metastatic Colorectal Cancer: From Current Treatment Strategies to Future Perspectives
Mizukami, T., Izawa, N., Nakajima, T. E., & Sunakawa, Y. (2019) · Drugs · doi:10.1007/s40265-019-01113-0 · Cited by 62
Variants and Pitfalls in PET/CT Imaging of Gastrointestinal Cancers
Jayaprakasam, V. S., Paroder, V., & Schöder, H. M. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2021.04.001 · Cited by 61
Preclinical models as patients’ avatars for precision medicine in colorectal cancer: past and future challenges
Durinikova, E., Buzo, K., & Arena, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01981-z · Cited by 61
Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3–5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis
Nieuwenhuizen, S., Dijkstra, M., Puijk, R. S., Geboers, B., Ruarus, A. H., Schouten, E. A. C., Nielsen, K., de Vries, J. J. J., Bruynzeel, A. M. E., Scheffer, H. J., et al. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01248-6 · Cited by 61
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer WithERBB2Amplification orERBB2/3Mutations: Results From the TAPUR Study
Gupta, R., Meric‐Bernstam, F., Rothe, M., Garrett-Mayer, E. S., Mangat, P. K., D’Andre, S. D., Ahn, E. R., O'Lone, R., Halabi, S., Grantham, G. N., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00306 · Cited by 72
Next-generation nanocarriers for colorectal cancer: passive, active, and stimuli-responsive strategies for precision therapy
Mohamed, R. A., Ali, S. M., Ahmed, I. S., Rawas‐Qalaji, M., & Hussain, Z. (2025) · Biomaterials Science · doi:10.1039/d5bm01176k · Cited by 63
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
Gómez‐España, M. A., Gallego-Plazas, J., González‐Flores, E., Maurel, J., Páez, D., Sastre, J., Aparicio, J., Benavides, M., Feliú, J., & Vera, R. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02002-w · Cited by 62
Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
Satake, H., Kato, T., Oba, K., Kotaka, M., Kagawa, Y., Yasui, H., Nakamura, M., Watanabe, T., Matsumoto, T., Kii, T., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0643 · Cited by 61
Self-citation
Circulating tumor DNA for prognosis assessment and postoperative management after curative‐intent resection of colorectal liver metastases
Reinert, T., Petersen, L. M. S., Henriksen, T. V., Larsen, M. Ø., Rasmussen, M. H., Johansen, A. F. B., Øgaard, N., Knudsen, M., Nordentoft, I., Vang, S., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.33924 · Cited by 62
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61
Self-citation
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
Cutsem, E. V., Danielewicz, I., Saunders, M. P., Pfeiffer, P., Argilés, G., Borg, C., Glynne‐Jones, R., Punt, C. J. A., van de Wouw, A. J., Fedyanin, M. Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.024 · Cited by 60
Self-citation
Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board
Heinrich, K., Miller‐Phillips, L., Ziemann, F., Hasselmann, K., Rühlmann, K., Flach, M., Biro, D., von Bergwelt‐Baildon, M., Holch, J. W., Herold, T., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04165-0 · Cited by 62
Self-citation
The Purified Extract from the Medicinal Plant Bacopa monnieri, Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by Inducing Cell Cycle Arrest and Apoptosis
Smith, E., Palethorpe, H. M., Tomita, Y., Pei, J. V., Townsend, A. R., Price, T. J., Young, J. P., Yool, A. J., & Hardingham, J. E. (2018) · Cells · doi:10.3390/cells7070081 · Cited by 60
Self-citation
Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice
Ragusa, S., Prat-Luri, B., González-Loyola, A., Nassiri, S., Squadrito, M. L., Guichard, A., Cavin, S., Gjorevski, N., Barras, D., Marra, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129558 · Cited by 56
Surgical management of recurrent colon cancer
Brown, K. G. M., & Koh, C. (2020) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-2019-ccm-09 · Cited by 59
Recurrence at surgical margin following hepatectomy for colorectal liver metastases is not associated with R1 resection and does not impact survival
Andreou, A., Knitter, S., Schmelzle, M., Kradolfer, D., Maurer, M. H., Auer, T. A., Fehrenbach, U., Lachenmayer, A., Banz, V. M., Schöning, W., et al. (2020) · Surgery · doi:10.1016/j.surg.2020.11.024 · Cited by 59
Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature
Guo, M. Z., Jin, N. Y., Pawlik, T. M., & Cloyd, J. M. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i9.1043 · Cited by 60
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023
Akahoshi, K., Shindoh, J., Tanabe, M., Ariizumi, S., Eguchi, S., Okamura, Y., Kaibori, M., Kubo, S., Shimada, M., Taketomi, A., et al. (2024) · Liver Cancer · doi:10.1159/000538627 · Cited by 59
Radiofrequency ablation versus resection for technically resectable colorectal liver metastasis: a propensity score analysis
Wang, L., Zhang, Z.-Y., Yan, X., Yang, W., Yan, K., & Xing, B.-C. (2018) · World Journal of Surgical Oncology · doi:10.1186/s12957-018-1494-3 · Cited by 59
Paclitaxel loaded EDC-crosslinked fibroin nanoparticles: a potential approach for colon cancer treatment
Phạm, D. T., Saelim, N., & Tiyaboonchai, W. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00682-7 · Cited by 59
Developments in zebrafish avatars as radiotherapy sensitivity reporters — towards personalized medicine
Costa, B. F., Ferreira, S., Póvoa, V., Cardoso, M. J., Vieira, S. C., Stroom, J. C., Fidalgo, P. O., Rio‐Tinto, R., Figueiredo, N., Parés, O., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.039 · Cited by 58
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?
Martini, G., Ciardiello, D., Vitiello, P. P., Napolitano, S., Cardone, C., Cuomo, A., Troiani, T., Ciardiello, F., & Martinelli, E. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102023 · Cited by 59
Self-citation
Nutritional and inflammatory measures predict survival of patients with stage IV colorectal cancer
Takamizawa, Y., Shida, D., Boku, N., Nakamura, Y., Ahiko, Y., Yoshida, T., Tanabe, T., Takashima, A., & Kanemitsu, Y. (2020) · BMC Cancer · doi:10.1186/s12885-020-07560-3 · Cited by 58
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR
Palacín-Aliana, I., Garcia‐Romero, N., Asensi-Puig, A., Carrión-Navarro, J., González‐Rumayor, V., & Ayuso‐Sacido, Á. (2021) · Biomedicines · doi:10.3390/biomedicines9080906 · Cited by 63
The role of image-guided therapy in the management of colorectal cancer metastatic disease
de Baère, T., Tselikas, L., Yevich, S. M., Boige, V., Deschamps, F., Ducreux, M. P., Goèré, D., Nguyen, F., & Malka, D. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.010 · Cited by 58
Self-citation
Methylation-Based Therapies for Colorectal Cancer
Cervena, K., Siskova, A., Buchler, T., Vodicka, P., & Vymetalkova, V. (2020) · Cells · doi:10.3390/cells9061540 · Cited by 57
Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer
Dyhl-Polk, A., Vaage‐Nilsen, M., Schou, M., Vistisen, K. K., Lund, C. M., Kümler, T., Appel, J. M., & Nielsen, D. L. (2020) · Acta Oncologica · doi:10.1080/0284186x.2019.1711164 · Cited by 57
Baicalein is a novel TLR4‐targeting therapeutics agent that inhibits TLR4/HIF‐1α/VEGF signaling pathway in colorectal cancer
Chen, M., Zhong, K., Tan, J., Meng, M., Liu, C. M., Chen, B., Huang, C., Wong, H. L. X., Bian, Z., Su, T., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.564 · Cited by 57
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer
Parikh, A. R., Lee, F.-C., Yau, L., Koh, H. A., Knost, J. A., Mitchell, E. P., Bosanac, I., Choong, N. W., Scappaticci, F. A., Mancao, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1221 · Cited by 57
Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience
Vitiello, P. P., Falco, V. D., Giunta, E. F., Ciardiello, D., Cardone, C., Vitale, P., Zanaletti, N., Borrelli, C., Poliero, L., Terminiello, M., et al. (2019) · Cancers · doi:10.3390/cancers11101504 · Cited by 60
Self-citation
Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial
Cutsem, E. V., Paccard, C., Chiron, M., & Tabernero, J. M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1985 · Cited by 57
Self-citation
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
Marmorino, F., Boccaccino, A., Germani, M. M., Falcone, A., & Cremolini, C. (2020) · Cancers · doi:10.3390/cancers12082317 · Cited by 58
Self-citation
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis
Tabernero, J. M., Argilés, G., Sobrero, A. F., Borg, C., Ohtsu, A., Mayer, R. J., Vidot, L., Vera, S. R. M., & Cutsem, E. V. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000752 · Cited by 58
Self-citation

Authors: Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., Ciardiello, F., D'Hoore, A., Diaz-Rubio, E., Douillard, J.-Y., Ducreux, M., Falcone, A., Grothey, A., Gruenberger, T., Haustermans, K., Heinemann, V., Hoff, P., Köhne, C.-H., Labianca, R., Laurent-Puig, P., Ma, B., Maughan, T., Muro, K., Normanno, N., Österlund, P., Oyen, W. J. G., Papamichael, D., Pentheroudakis, G., Pfeiffer, P., Price, T. J., Punt, C., Ricke, J., Roth, A., Salazar, R., Scheithauer, W., Schmoll, H. J., Tabernero, J., Taïeb, J., Tejpar, S., Wasan, H., Yoshino, T., Zaanan, A., & Arnold, D.
Affiliations: Universitat de València (ES)
Hôpital Paul-Brousse (FR)
Ospedale Policlinico San Martino (IT)
Tel Aviv University (IL)
University of Turin (IT)
Northwestern Medicine (US)
Unified Szent István and Szent László Hospital (HU)
University of Campania "Luigi Vanvitelli" (IT)
Institut de Cancérologie de l'Ouest (FR)
Université Paris-Saclay (FR)
University of Pisa (IT)
Mayo Clinic (US)
Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
KU Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
Universidade de São Paulo (BR)
Klinikum Oldenburg (DE)
Ospedale Papa Giovanni XXIII (IT)
Chinese University of Hong Kong (HK)
University of Oxford (GB)
Aichi Cancer Center (JP)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Institute of Cancer Research (GB)
Bank of Cyprus Oncology Center (CY)
University of Ioannina (GR)
Odense University Hospital (DK)
Queen Elizabeth Hospital (AU)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Magdeburg (DE)
University Hospital of Geneva (CH)
Institut Català d'Oncologia (ES)
Comprehensive Cancer Center Vienna (AT)
Martin Luther University Halle-Wittenberg (DE)
Vall d'Hebron Hospital Universitari (ES)
Universitair Ziekenhuis Leuven (BE)
Imperial College Healthcare NHS Trust (GB)
National Cancer Center Hospital East (JP)
Hôpital Européen Georges-Pompidou (FR)
ORCID: Cervantes, A.
Adam, R.
Sobrero, A.
Bardelli, A.
Benson, A.
Bodoky, G.
Ciardiello, F.
Douillard, J.-Y.
Ducreux, M.
Falcone, A.
Grothey, A.
Gruenberger, T.
Haustermans, K.
Heinemann, V.
Hoff, P.
Labianca, R.
Ma, B.
Maughan, T.
Muro, K.
Normanno, N.
Oyen, W.J.G.
Papamichael, D.
Pentheroudakis, G.
Pfeiffer, P.
Price, T.J.
Punt, C.
Ricke, J.
Salazar, R.
Schmoll, H.J.
Tabernero, J.
Tejpar, S.
Wasan, H.
Yoshino, T.
Zaanan, A.
Arnold, D.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2016-08
Volume: 27
Issue: 8
Pages: 1386-1422
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdw235
OpenAlex: W2470575266
Cited by: 3,421
References: 309
Citations by year: 2026: 199 · 2025: 236 · 2024: 297 · 2023: 364 · 2022: 481 · 2021: 518 · 2020: 444 · 2019: 365 · 2018: 279 · 2017: 189 · 2016: 39
FWCI: 155.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1191 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Data Archiving and Networked Services (DANS) (submittedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Lirias (submittedVersion)
HighWire Press Open Archive (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
Funders: Cancer Research UK (13363)
National Institute for Health and Care Research (11/100/50)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
Keywords: metastatic colorectal cancer, colorectal cancer, surgical resection of metastases, systemic therapy, multidisciplinary management, treatment decision-making, evidence-based recommendations
MeSH terms: Humans, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Guidelines as Topic, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks